Achieving Good Manufacturing Production (GxP) compliance with NGS

The new guidelines the viral safety evaluation of biotechnology products from the International Council for Harmonisation (ICH) recommend replacing multiple in vivo and in vitro assays with next-generation sequencing (NGS) to maintain good manufacturing practices.

If that sounds like a lot, we’ve got you covered. In this webinar, we’ll explore how you can easily apply NGS analysis to GxP with the QIAGEN CLC Genomics platform. Make compliance intrinsic to your workflow and ensure product quality, data integrity and patient safety.

You’ll learn how to:

Assess biosafety, ensure integrity and perform quality control in the biotech industry with NGS
Implement and maintain GxP with the QIAGEN CLC Genomics platform
Add your existing applications and extend their use through the CLC interface

About the speaker

Leif Schauser, Ph.D., Director Product Management Genome Analysis, Bioinformatics

QIAGEN

Leif Schauser holds a PhD in plant molecular genetics from Aarhus University, Denmark. He did his postdoctoral training in Norwich, UK, before working as a professor in bioinformatics at Aarhus University. In 2013 Leif joined CLC bio, just before its acquisition by QIAGEN. During his time at QIAGEN, Leif has worked with many aspects of bioinformatics, ranging from microbial genomics and metagenomics to biomedical applications.